Funding for this research was provided by:
National Natural Science Foundation of China (81400134, 81400152, 81470302, 81730006, 81421002)
Tianjin Municipal Science and Technology Commission Grant (15JCZDJC35800)
CAMS Initiative for Innovative Medicine (2016-I2M-1-018, 2016-I2M-1-017, 2016GH3100001)
Novo Nordisk Hemophilia Research Fund
the Ministry of Science and Technology of China (2016YFA0100600)
Text and Data Mining valid from 2018-04-06
Received: 6 October 2017
Revised: 22 February 2018
Accepted: 13 March 2018
First Online: 6 April 2018
: LZ is a member of the hemostasis and thrombosis group of Chinese Medical Association Hematology and a Chinese editorial board of Haemophilia, an official journal of the World Federation of hemophilia. For many years he engaged in the research of hemophilia, idiopathic thrombocytopenic purpura (ITP), and essential thrombocythemia (ET), including clinical work and basis study. He is also involved in a variety of stem cell research, including stem cell engineering, industrial platform construction, the establishment of stem cell separation, efficient amplification, frozen storage and recovery, and large-scale production of cellular products.
: The study was approved by the Ethics Committee of the Institute of Hematology and Blood Disease Hospital, Chinese Academy of Medical Sciences, informed consent was obtained from the participant and his legal guardians, and ethics approval for NOD/SCID mice was obtained.
: The participant and his legal guardians declare their support for the publication and its contents.
: The authors declare that they have no competing interests.
: Springer Nature remains neutral with regard to jurisdictional claims in published maps and institutional affiliations.